|Bid||0.1905 x 1100|
|Ask||0.1986 x 1000|
|Day's Range||0.1984 - 0.2285|
|52 Week Range||0.1700 - 0.8800|
|Beta (5Y Monthly)||3.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 23, 2022 - Mar 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.23|
EMERYVILLE, Calif., May 12, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2022 and provides a business update. Financial results for the first quarter of 2022 include the operations of the DERMAdoctor business, which was acquired on November 5, 2021.
EMERYVILLE, Calif., May 09, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces the expansion of its top-selling Kakadu C and Calm Cool + Corrected product lines with the introduction of next-generation products that are uniquely formulated with anti-aging ingredients to help reduce the appearance of wrinkles, fine lines, pores and discoloration.
EMERYVILLE, Calif., May 05, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2022 after market close on Thursday, May 12, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.